Rhythm Pharmaceuticals
RYTM
87 hedge funds and large institutions have $846M invested in Rhythm Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 4 closing their positions.
325% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 4
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
18% more funds holding
Funds holding: 74 → 87 (+13)
16% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 25
1% less capital invested
Capital invested by funds: $851M → $846M (-$4.87M)
2.35% less ownership
Funds ownership: 92% → 89.65% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.15M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2M |
| 3 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$1.44M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.26M |
| 5 |
SIM
Spark Investment Management
New York
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TG
TRV GP
Boston,
Massachusetts
|
-$28.7M |
| 2 |
O
OrbiMed
New York
|
-$4.06M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.89M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.88M |
| 5 |
Citigroup
New York
|
-$1.86M |
RYTM Hedge Fund Activity: Q1 2019 in Review
87 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2019, worth a combined $846M — down 0.57% from $851M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RYTM positions and 4 closed out — a net gain of 13 holders — while 29 added to existing stakes and 25 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $6.15M. The largest seller was TRV GP, cutting an estimated $28.7M.
- 87 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2019, up from 74 in Q4 2018.
- Funds reported $846M of Rhythm Pharmaceuticals stock for Q1 2019, down 0.57% quarter-over-quarter.
- 17 funds opened new Rhythm Pharmaceuticals positions in Q1 2019 and 4 closed out, a net change of +13 holders.
- The largest Rhythm Pharmaceuticals buyer in Q1 2019 was T. Rowe Price Associates, an estimated $6.15M added.
- The largest Rhythm Pharmaceuticals seller in Q1 2019 was TRV GP, an estimated $28.7M sold.
Based on aggregated 13F filings for Q1 2019.